Cargando…
SynPharm: A Guide to PHARMACOLOGY Database Tool for Designing Drug Control into Engineered Proteins
[Image: see text] A major challenge in synthetic biology, particularly for mammalian systems, is the inclusion of adequate external control for the synthetic system activities. Control at the transcriptional level can be achieved by adaptation of bacterial repressor–operator systems (e.g., TetR), bu...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2018
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6068591/ https://www.ncbi.nlm.nih.gov/pubmed/30087931 http://dx.doi.org/10.1021/acsomega.8b00659 |
_version_ | 1783343304373436416 |
---|---|
author | Ireland, Sam M. Southan, Christopher Dominguez-Monedero, Alazne Harding, Simon D. Sharman, Joanna L. Davies, Jamie A. |
author_facet | Ireland, Sam M. Southan, Christopher Dominguez-Monedero, Alazne Harding, Simon D. Sharman, Joanna L. Davies, Jamie A. |
author_sort | Ireland, Sam M. |
collection | PubMed |
description | [Image: see text] A major challenge in synthetic biology, particularly for mammalian systems, is the inclusion of adequate external control for the synthetic system activities. Control at the transcriptional level can be achieved by adaptation of bacterial repressor–operator systems (e.g., TetR), but altering the activity of a protein by controlling transcription is indirect and for longer half-life mRNAs, decreasing activity this way can be inconveniently slow. Where possible, direct modulation of protein activity by soluble ligands has many advantages, including rapid action. Decades of drug discovery and pharmacological research have uncovered detailed information on the interactions between large numbers of small molecules and their primary protein targets (as well as off-target secondary interactions), many of which have been well studied in mammals, including humans. In principle, this accumulated knowledge would be a powerful resource for synthetic biology. Here, we present SynPharm, a tool that draws together information from the pharmacological database GtoPdb and the structural database, PDB, to help synthetic biologists identify ligand-binding domains of natural proteins. Consequently, as sequence cassettes, these may be suitable for building into engineered proteins to confer small-molecule modulation on them. The tool has ancillary utilities which include assessing contact changes among different ligands in the same protein, predicting possible effects of genetic variants on binding residues, and insights into ligand cross-reactivity among species. |
format | Online Article Text |
id | pubmed-6068591 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | American Chemical Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-60685912018-08-05 SynPharm: A Guide to PHARMACOLOGY Database Tool for Designing Drug Control into Engineered Proteins Ireland, Sam M. Southan, Christopher Dominguez-Monedero, Alazne Harding, Simon D. Sharman, Joanna L. Davies, Jamie A. ACS Omega [Image: see text] A major challenge in synthetic biology, particularly for mammalian systems, is the inclusion of adequate external control for the synthetic system activities. Control at the transcriptional level can be achieved by adaptation of bacterial repressor–operator systems (e.g., TetR), but altering the activity of a protein by controlling transcription is indirect and for longer half-life mRNAs, decreasing activity this way can be inconveniently slow. Where possible, direct modulation of protein activity by soluble ligands has many advantages, including rapid action. Decades of drug discovery and pharmacological research have uncovered detailed information on the interactions between large numbers of small molecules and their primary protein targets (as well as off-target secondary interactions), many of which have been well studied in mammals, including humans. In principle, this accumulated knowledge would be a powerful resource for synthetic biology. Here, we present SynPharm, a tool that draws together information from the pharmacological database GtoPdb and the structural database, PDB, to help synthetic biologists identify ligand-binding domains of natural proteins. Consequently, as sequence cassettes, these may be suitable for building into engineered proteins to confer small-molecule modulation on them. The tool has ancillary utilities which include assessing contact changes among different ligands in the same protein, predicting possible effects of genetic variants on binding residues, and insights into ligand cross-reactivity among species. American Chemical Society 2018-07-18 /pmc/articles/PMC6068591/ /pubmed/30087931 http://dx.doi.org/10.1021/acsomega.8b00659 Text en Copyright © 2018 American Chemical Society This is an open access article published under a Creative Commons Attribution (CC-BY) License (http://pubs.acs.org/page/policy/authorchoice_ccby_termsofuse.html) , which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited. |
spellingShingle | Ireland, Sam M. Southan, Christopher Dominguez-Monedero, Alazne Harding, Simon D. Sharman, Joanna L. Davies, Jamie A. SynPharm: A Guide to PHARMACOLOGY Database Tool for Designing Drug Control into Engineered Proteins |
title | SynPharm: A Guide to PHARMACOLOGY Database Tool for
Designing Drug Control into
Engineered Proteins |
title_full | SynPharm: A Guide to PHARMACOLOGY Database Tool for
Designing Drug Control into
Engineered Proteins |
title_fullStr | SynPharm: A Guide to PHARMACOLOGY Database Tool for
Designing Drug Control into
Engineered Proteins |
title_full_unstemmed | SynPharm: A Guide to PHARMACOLOGY Database Tool for
Designing Drug Control into
Engineered Proteins |
title_short | SynPharm: A Guide to PHARMACOLOGY Database Tool for
Designing Drug Control into
Engineered Proteins |
title_sort | synpharm: a guide to pharmacology database tool for
designing drug control into
engineered proteins |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6068591/ https://www.ncbi.nlm.nih.gov/pubmed/30087931 http://dx.doi.org/10.1021/acsomega.8b00659 |
work_keys_str_mv | AT irelandsamm synpharmaguidetopharmacologydatabasetoolfordesigningdrugcontrolintoengineeredproteins AT southanchristopher synpharmaguidetopharmacologydatabasetoolfordesigningdrugcontrolintoengineeredproteins AT dominguezmonederoalazne synpharmaguidetopharmacologydatabasetoolfordesigningdrugcontrolintoengineeredproteins AT hardingsimond synpharmaguidetopharmacologydatabasetoolfordesigningdrugcontrolintoengineeredproteins AT sharmanjoannal synpharmaguidetopharmacologydatabasetoolfordesigningdrugcontrolintoengineeredproteins AT daviesjamiea synpharmaguidetopharmacologydatabasetoolfordesigningdrugcontrolintoengineeredproteins |